

SENATE BILL 336

J1

6lr2062
CF HB 427

By: Senator Feldman

Introduced and read first time: January 23, 2026

Assigned to: Finance

A BILL ENTITLED

1 AN ACT concerning

2 **Task Force on Responsible Use of Natural Psychedelic Substances – Extension**

3 FOR the purpose of extending the Task Force on Responsible Use of Natural Psychedelic
4 Substances to study and make recommendations related to the use of natural
5 psychedelic substances; and generally relating to the Task Force on Responsible Use
6 of Natural Psychedelic Substances.

7 BY repealing and reenacting, with amendments,
8 Chapter 793 of the Acts of the General Assembly of 2024
9 Section 1 and 2

10 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
11 That the Laws of Maryland read as follows:

12 **Chapter 793 of the Acts of 2024**

13 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
14 That:

15 (a) (1) In this section, “natural psychedelic substances” includes naturally
16 derived psilocybin, psilocin, dimethyltryptamine, mescaline, and any other substance
17 determined by the Task Force to be a natural psychedelic substance.

18 (2) “Natural psychedelic substances” does not include peyote.

19 (b) There is a Task Force on Responsible Use of Natural Psychedelic Substances.

20 (c) The Task Force consists of the following members:

21 (1) one member of the Senate of Maryland who shall be appointed by the
22 President of the Senate;

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



(2) one member of the House of Delegates who shall be appointed by the
the House;

(3) the Secretary of Health, or the Secretary's designee;

(4) the Secretary of Disabilities, or the Secretary's designee;

(5) the Secretary of Veterans Affairs, or the Secretary's designee;

(6) the Director of the Maryland Cannabis Administration, or the
esignee; and

(7) the following members, appointed by the Governor:

(i) one representative of the University System of Maryland, the Johns University's Center for Psychedelic and Consciousness Research, or Pratt;

(ii) one representative of a Native American tribe with experience in the use and spiritual use of psychedelic substances;

(iii) one individual with expertise in behavioral health;

(iv) one individual with expertise in the treatment of substance use

(v) one individual with expertise in the treatment of chronic pain;

(vi) one individual with expertise in psychedelic-assisted therapy;

(vii) one individual with expertise in psychedelic research;

(viii) one individual with expertise in access to care in underserved
s;

(ix) one individual with expertise in drug policy reform;

(x) one individual with expertise as a member of law enforcement;

(xi) one individual who is a patient with conditions that can be relieved by the use of psychedelic substances;

(xii) one individual with experience with the pharmacology of natural substances; and

(xiii) one physician with experience with the appropriate use of psychedelic substances and other integrative medical practices.

3 (d) To the extent practicable, the membership of the Task Force shall reflect the
4 socioeconomic, ethnic, and geographic diversity of the State.

5 (e) The Governor shall designate the chair of the Task Force.

6 (f) The Maryland Cannabis Administration shall provide staff for the Task Force.

7 (g) A member of the Task Force:

8 (1) may not receive compensation as a member of the Task Force; but

11 (h) The Task Force shall:

12 (1) study:

13 (i) existing laws, policies, and practices relating to the use of natural
14 psychedelic substances;

15 (ii) the best available science and data on public benefits of
16 responsible access to and use of natural psychedelic substances;

17 (iii) opportunities to maximize public benefits of responsible access to
18 and use of natural psychedelic substances;

19 (iv) the best available data on potential risks of access to and use of
20 natural psychedelic substances;

21 (v) opportunities to mitigate potential risks of access to and use of
22 natural psychedelic substances; and

23 (vi) barriers health care practitioners and facilitators may encounter
24 relating to natural psychedelic substances, including barriers relating to insurance,
25 restrictions by licensing and credentialing entities, zoning, advertising, and financial
26 services;

27 (2) make recommendations regarding any changes to State law, policy, and
28 practices needed to create a Maryland Natural Psychedelic Substance Access Program that
29 enables broad, equitable, and affordable access to psychedelic substances, including:

30 (i) permitting requirements, including requirements regarding
31 education and safety;

(ii) access to treatment and regulated support; and

(iii) production of natural psychedelic substances; and

(3) make recommendations to transition from criminalizing conduct involving natural psychedelic substances, including:

5 (i) punishing with civil penalties nonviolent infractions involving
6 the planting, cultivating, purchasing, transporting, distributing, or possessing of or other
7 engagement with natural psychedelic substances;

(ii) expunging the records of Marylanders with convictions for nonviolent criminal offenses relating to natural psychedelic substances; and

(iii) releasing Marylanders incarcerated for nonviolent criminal offenses relating to natural psychedelic substances.

12 (i) The Task Force may consult with experts and stakeholders in conducting its
13 duties.

21 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July
22 1, 2024. It shall remain effective for a period of [2] 3 years and 6 months and, at the end of
23 December 31, [2026] 2027, this Act, with no further action required by the General
24 Assembly, shall be abrogated and of no further force and effect.

25 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July
26 1, 2026.